No Significant Changes of Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Kidney Disease by Switching from Linagliptin to Teneligliptin.

Keiji HiraiHiroaki NonakaMoeka UedaJunki MorinoShohei KanekoSaori MinatoYuko MutsuyoshiKatsunori YanaiHiroki IshiiMomoko MatsuyamaTaisuke KitanoAkinori AomatsuHaruhisa MiyazawaKiyonori ItoYuichiro UedaSusumu OokawaraYoshiyuki Morishita

Published in: Pragmatic and observational research (2021)

Switching from linagliptin to teneligliptin may not improve glycemic control, reduce urinary protein excretion, or ameliorate the rate of renal function decline in patients with advanced-stage diabetic kidney disease. These results suggest that teneligliptin may not be more advantageous for glycemic control and renoprotection compared with linagliptin in patients with advanced-stage diabetic kidney disease.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
wound healing
insulin resistance
metabolic syndrome
binding protein
protein protein